Table 2. Incidence of P. vivax infection following treatment.
| No. | Post-treatment P. vivax | Incidence rate Pv/1000 over 30 days of follow-up | P. vivax detected at Day 0 by PCR | Median day of onset of P. vivax following treatment (range) | |
| ARC1 2006–7 | 107 | 32 | 330.7 | 3/28 * (11%) | 28 (14–28) |
| Artesunate | 72 | 21 | 326.4 | 2 | 24 (14–28) |
| Quinine/tetracycline | 35 | 11 | 339.2 | 1 | 28 (21–28) |
| ARC2 2008–9 | |||||
| Artesunate** | 136 | 27 | 147.8 | 2/27 (7.4%) | 28 (21–42) |
| AS2 | 72 | 12 | 122.7 | 1 | 32 (21–42) |
| AS4 | 38 | 7 | 133.3 | 0 | 35 (21–42) |
| AS6 | 26 | 8 | 246.7 | 1 | 25(21–42) |
| Total combined | 243 | 59 | 211.1 | 5/55 (9.1%) | 28 (14–42) |
*4 Day 0 samples were not available.
**Artesunate was dosed at 2 vs. 4 vs. 6 mg/kg/day×7 days.